Dawn Connelly
Senior Features Editor at The Pharmaceutical Journal
Senior features editor @PJOnline_News @absw Feature of the Year 2023 and @Avicennaplc Pharmacy Writer of the Year 2023 Tweets are my own.
Articles
-
4 weeks ago |
pharmaceutical-journal.com | Dawn Connelly
The narrowing of the ethnicity awarding gap for UK pharmacy graduates seen during the COVID-19 pandemic has not been sustained, according to an analysis by The Pharmaceutical Journal. Analysis of the latest data submitted by pharmacy schools to the Higher Education Statistics Agency suggests that the ethnicity awarding gap for graduates from MPharm degrees in the UK was 11 percentage points in 2021/2022 and 2022/2023 — an increase from 8 percentage points in 2019/2020 and 2020/2021.
-
4 weeks ago |
pharmaceutical-journal.com | Dawn Connelly |Wes Mountain
In 2021/2022, the ethnicity awarding gap for all UK graduates widened for the first time in seven years — and by “a substantial amount”, according to the charity Advance HE. Up until that point, the gap — the percentage point difference between the proportion of white students and minority ethnic students awarded a first or 2:1 — had been getting incrementally narrower, with the gap closing significantly in 2019/2020 during the COVID-19 pandemic, when learning and assessments moved online.
-
2 months ago |
pharmaceutical-journal.com | Dawn Connelly
Allergic rhinitis (AR) is a common inflammatory nasal condition that affects 10–15% of children and 26% of adults in the UK1. It impacts school attendance and performance in examinations and at work, as well affecting quality of life by disrupting sleep. It is also a risk factor for the development of asthma. Some people are more prone to allergic rhinitis than others.
-
2 months ago |
pharmaceutical-journal.com | Dawn Connelly
Fewer than 20,000 people in England have been prescribed anticholesterol drug inclisiran (Leqvio; Novartis) in primary care since 2021, despite expectations set by the NHS that 300,000 people would be taking the drug by 2024. A freedom of information request sent by The Pharmaceutical Journal to the NHS Business Services Authority (NHS BSA), revealed that 19,416 people were prescribed inclisiran in primary care in England in the three years between October 2021 and October 2024.
-
Jan 17, 2025 |
pharmaceutical-journal.com | Dawn Connelly
The number of children and young people prescribed melatonin in England has more than tripled over the past nine years, data analysed by The Pharmaceutical Journal has shown. A total of 117,093 patients aged 17 years or under were prescribed melatonin in the first quarter of 2024/2025, according to the data obtained under the Freedom of Information Act from the NHS Business Services Authority. This compares with 33,926 patients in the first quarter of 2015/2016, an increase of 245%.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 744
- Tweets
- 3K
- DMs Open
- Yes
CPCF arrangements for 2024/25 and 2025/26 announced https://t.co/JV1082II2E
RT @PJOnline_News: In this ‘Spotlight’ episode of #ThePJPod, @cbwickware & @DawnConnelly73 consider the current state of palliative care an…
RT @PJOnline_News: This month's infographic by @DawnConnelly73 and @therevmountain reveals exclusive data analysis by #ThePJ that shows how…